Pengaruh Beban Pendinginan terhadap Temperatur Sistem Residential Air Conditioning Hibrida dengan Kondensor Dummy Tipe Multi Helical Coil Menggunakan Refrigeran Hidrokarbon

One way to save the energy is to improve the energy efficiency with combining two different equipmentsbecome one new double-function or hybrid equipment. Hybrid air conditioning can improve energy efficiency byremoving waste heat to the environment through condenser for heating water. The objective of this experimentalstudy is to investigate the effect of cooling load to system temperature of vapor-compression cycle hybrid airconditioning system with multi helical tipe of dummy condenser. The test was conducted with several coolingload variations (0, 1000, 2000 and 3000 Watt) as residential cooling load simulation. The result showed that therefrigerant temperature while using HCR-22 was obtained about 67.47 °C to 72.93 °C. The temperature ofrefrigerant was increased as well as the applied cooling load to be increased. The temperature of refrigeranthad more heat which to be absorbed and released into the environment so that the produced water temperaturewasalso increased. Hot water temperature of the ACWH system using HCR-22 refrigerant was obtained about41.01-44.96 ˚C

Analisis Kuat Tarik Kayu Menggunakan PKKNI 1961 dan SNI 7973:2013

Use of wood construction in Indonesia is decrease significant than concrete and steel. While it is, government by National Standardization Corporation (BSN) had been published Indonesian National Standard about Wood Construction Design Spesification with code SNI 7973:2013. This code absolutly influential the old code which is PKKNI 1961. SNI 7973:2013 is regulate about Load Resistance Factor Design (LRFD) and Allowable Stress Design (ASD), while PKKNI 1961 juts use ASD method. In case SNI 7973:2013 have been use ASD, but it is different to PKKNI 1961. This research is would to find the different betwen SNI 7973:2013 and PKKNI 1961 to tension member with dimention 5/10, 6/12, 8/12 and 10/10. Result of research to tension member show that LRFD 100%, ASD 65,1% and PKKNI 111,4%

Kajian Kinerja Bagian Jalinan (Studi Kasus : Jl. Niaga 1 – Jl. Yos Sudarso, Kota Tarakan)

This study aims to determine the performance on a single weave that occurred on Jl.Niaga I - Jl. Yos Sudarso, Tarakan City. The performance is capacity, degree of saturation, speed, and travel time. With these performance parameters serve as based of planning in transportation infrastructure. The results of this study are also expected to provide recommendations to users, planners and policy makers in an effort to solve traffic problems, especially to reduce the delay that occurs in a single wave that occurred on Jl Niaga I-Jl. Yos Sudarso Kota Tarakan

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo